News | January 20, 2026
Syngene locks in Bristol Myers Squibb alliance through 2035
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
The antibody was designed and developed at Abzena’s Cambridge, UK,
The event will be attended by 35,000+ industry professionals
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Subscribe To Our Newsletter & Stay Updated
